BioSpace News Archive

Ionis Pharmaceuticals, Inc. announced that its partner Roche, also known as Genentech in the United States, has completed enrollment for GENERATION HD1, a global Phase 3 study evaluating the efficacy and safety of tominersen, an investigational antisense therapy for people living with Huntington’s disease.

Conference Call to Discuss Preliminary Clinical Data Being Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting I

Opdivo plus Yervoy prolonged survival compared to chemotherapy at interim analysis in CheckMate -743

Alligator Bioscience, announced that the company’s Nomination Committee, following an initiative from all members of the Board of Directors, proposes that the fees to board-members are reduced with 20 percent compared to the Nomination Committee’s original proposal to the Annual General Meeting to be held on May 5.

Medable Inc. announced a multi-company research framework to accelerate development of diagnostics and treatments for COVID-19, providing individuals fast access to participate in leading-edge research for diagnostics, health monitoring and interventional clinical trials.

Study met primary endpoint of significantly improving progression-free survival, and secondary endpoints of overall survival and objective response rate vs. sunitinib

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has entered into an agreement with

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics and software, today announced the availability of the IDEXX SARS-CoV-2 (COVID-19) RealPCR™ Test for pets. IDEXX is launching the test in res

Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that the KidneyIntelX™ platform will be used by investigators from the Icahn School of Medicine at Mount Sinai to assess the risk of adverse kidney events in patients diagnosed wi

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that it has received a Notice of Deficiency (“NOD”) for its avanafil New Drug Submission (NDS). Health Canada has requested the provision of additional quality information related to the avanafil drug substance in alignment with Intern